Anumana named in Fierce Medtech's Fierce 15 for 2022

See Article

Anumana in the News

All Topics

Media Contact |

Press Release

Anumana Named to Fierce Medtech’s 2022 Fierce 15

AI-driven startup from nference and Mayo Clinic Platform positioned to transform cardiac care

March 20, 2023


Fierce Medtech's 2022 Fierce 15

Fierce Medtech: Since its humble beginnings back in 2012, the Fierce 15 has made a point of spotlighting the most exciting startups in medtech—those not only challenging the limits of both the tech and healthcare industries but also making real progress toward their lofty goals. The companies on this year’s list—which kicks off the second decade of Fierce Medtech’s Fierce 15—are setting the bar even higher. Anumana, a joint venture between Nference and the Mayo Clinic, is using artificial intelligence to dig into the peaks and valleys of standard electrocardiograms to pull out not-so-standard analyses.

March 20, 2023


How Doctors Use AI to Help Diagnose Patients

Wall Street Journal: At Mayo cardiology, an AI tool has helped doctors diagnose new cases of heart failure and cases of irregular heart rhythms, which are called atrial fibrillation, potentially years before they might otherwise have been detected, said Dr. Paul Friedman, chair of the clinic’s cardiology department in Rochester, Minn.

February 28, 2023


Global Electrophysiology Devices Market to Surpass US$ 20,069.2 Million by 2030, Says Coherent Market Insights (CMI)

Coherent Market Insights: The global electrophysiology devices market is expected to exhibit a CAGR of 12.6% during the forecast period due to the increasing organic strategies such as acquisition by the key market players. For instance, in November 2022, anumana, Inc., a health technology company, announced that they had acquired NeuTrace, a medical technology company. This acquisition will help anumana, Inc., for the development of electrophysiology platform.

February 14, 2023


AI specialists ink deal with Pfizer to target cardiac amyloidosis

Cardiovascular Business: Anumana, a Massachusetts-based healthcare technology company focused on artificial intelligence (AI), has announced a new multi-year deal with Pfizer focused on improving the identification and diagnosis of cardiac amyloidosis. The groups will work to develop a new AI algorithm capable of identifying signs of cardiac amyloidosis—a significant heart issue that can lead to heart failure—in electrocardiogram (ECG) results.

December 20, 2022

of 17

Download Our One-Pager

Featuring key corporate highlights and an overview of Anumana's technology